Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:13 PM
Ignite Modification Date:
2025-12-24 @ 4:13 PM
NCT ID:
NCT06161766
Eligibility Criteria:
Inclusion Criteria:
* Patients with cirrhosis confirmed by histology or liver stiffness or with unequivocal signs in ultrasound, endoscopy and/or blood tests hospitalized between 1st of January 2018 and 31st of December 2022.
* Evidence of ascites due to portal hypertension
* Clinical suspicion of HRS-AKI or HRS-AKI-like syndrome (in case of previously diagnosed CKD)
* Pre-existing data on kidney function (SCr and eGFR) minimum 3 months prior to admission in a stable situation
* Dip stick urine test results (screening for proteinuria and hematuria) before initiation of AKI-treatment
* Vasoactive treatment for the management of HRS-AKI, as defined by the administration of terlipressin or noradrenalin plus albumin
* Age ≥ 18 years old
Exclusion Criteria:
* Uncontrolled shock
* Patients with cardiac cirrhosis as defined by the development of cirrhosis in a patient with chronic heart failure due to a primary cardiac disease (ischemic cardiomyopathy, hypertensive cardiomyopathy, etc.)
* Patients with hepatocellular carcinoma BCLC C or D
* Patients receiving renal replacement therapy at baseline
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06161766
Study Brief:
Protocol Section:
NCT06161766